FDA eases drug scrutiny for Indian Pharma over shortage in US


2020-05-18 17:28:52

Credit: pixabay.com

Credit: pixabay.com

Most of the Indian pharma plants that received inspection outcomes from the US regulator during the past two months or so, have received positive outcomes. As Indian drug majors have gradually improved their compliance, in the backdrop of high drug shortages in the US, analysts see this is as a positive for pharma exports.

Drug shortages have remained high this year in the US and the CLSA noted that the issue seems to be exacerbated when it comes to injectable products which account for over 60 per cent of the current drug shortages. India accounts for roughly 30 per cent of the generic drug supply to the US and it is a great opportunity for the players here.

Source: business-standard.com